

CITATION REPORT

List of articles citing

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site

DOI: 10.1016/j.radonc.2011.05.036

Radiotherapy and Oncology, 2011, 100, 33-40.

Source: <https://exaly.com/paper-pdf/50439155/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
496	The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature. 2012 , 2012, 945162		75
495	Treatment of hypopharyngeal carcinoma with primary chemoradiotherapy: functional morbidity. 2012 , 20, 89-96		11
494	Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription. 2012 , 23 Suppl 10, x178-85		32
493	EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab. 2012 , 2012, 901320		6
492	Oral and dental management for head and neck cancer patients treated by chemotherapy and radiotherapy. 2012 , 39, 135-8, 140		17
491	Bibliography. Head and neck. Current world literature. 2012 , 24, 345-9		
490	Facteurs pronostiques cliniques et histologiques des cancers localement avancés de la cavité buccale traités par chirurgie première. 2012 , 129, 339-344		
489	Evidence-based practice: management of glottic cancer. 2012 , 45, 1143-61		18
488	Clinical and histological prognostic factors in locally advanced oral cavity cancers treated with primary surgery. 2012 , 129, 291-6		12
487	Efficacy of super-selective neck dissection following chemoradiation for advanced head and neck cancer. <i>Oral Oncology</i> , 2012 , 48, 1185-9	4.4	17
486	Definitive radiotherapy for squamous cell carcinoma of the pyriform sinus. <i>Radiotherapy and Oncology</i> , 2012 , 105, 232-7	5.3	11
485	[Concurrent radiochemotherapy for the treatment of solid tumors]. 2012 , 188 Suppl 3, 263-71		5
484	Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors. 2012 , 7, 78		8
483	A population-based study of therapy and survival for patients with head and neck cancer treated in the community. 2012 , 118, 4452-61		39
482	The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. 2012 , 22, 198-206		13
481	Systemic therapy in head and neck cancer: changing paradigm. 2013 , 4, 19-26		7
480	Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results. 2014 , 271, 1673-8		5

479	Is open surgery for head and neck cancers truly declining?. 2013 , 270, 2793-802		16
478	A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. 2013 , 72, 545-52		13
477	Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. 2013 , 4, 327-33		27
476	Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. <i>Acta Oncologica</i> , 2013 , 52, 1257-71	3.2	42
475	Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. <i>Radiotherapy and Oncology</i> , 2013 , 109, 323-9	5.3	47
474	Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer. 2013 , 12, 535-41		22
473	Advances in radiation oncology for the management of oropharyngeal tumors. 2013 , 46, 629-43		5
472	Contemporary radiotherapy in head and neck cancer: balancing chance for cure with risk for complication. 2013 , 22, 579-98		13
471	Marital status and survival in patients with cancer. 2013 , 31, 3869-76		606
470	Lymph node positive head and neck carcinoma after curative radiochemotherapy: a long lasting debate on elective post-therapeutic neck dissections comes to a conclusion. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2013 , 17, 323-31	1.3	20
469	Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx. <i>Oral Oncology</i> , 2013 , 49, 454-60	4.4	20
468	Principles of Cytotoxic Chemotherapy. 2013 , 167-185		
467	Induction chemotherapy meta-analysis in head and neck cancer: right answer, wrong question. 2013 , 31, 2844-6		20
466	Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments. 2013 , 6, 663-76		9
465	Functional organ preservation in locally advanced laryngeal squamous cell carcinoma: is there a role for induction chemotherapy?. <i>Clinical Oncology</i> , 2013 , 25, 298-307	2.8	6
464	Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. <i>Oral Oncology</i> , 2013 , 49, 893-902	4.4	12
463	Low phosphorylated AKT expression in laryngeal cancer: indications for a higher metastatic risk. 2013 , 87, 349-55		6
462	Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013 , 116, 55-60	2	7

461	18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. 2013 , 54, 532-40		100
460	A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. <i>Radiotherapy and Oncology</i> , 2013 , 106, 333-40	53	56
459	[Current topics of team care for tongue and oral cancer]. 2013 , 116, 586-91		3
458	The Rapalogue, CCI-779, improves salivary gland function following radiation. 2014 , 9, e113183		20
457	Intensity-Modulated Radiotherapy with a Simultaneous Integrated Boost Combined with Chemotherapy in Stages III-IV Hypopharynx-Larynx Cancer: Treatment Compliance and Clinical Outcomes. 2014 , 2014, 1-7		1
456	Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options. 2014 , 15, 595-610		13
455	Induction chemotherapy followed by concurrent chemoradiotherapy for advanced stage oropharyngeal squamous cell carcinoma with HPV and P16 testing. 2014 , 123, 365-73		9
454	Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly or patients with poor performance. <i>Frontiers in Oncology</i> , 2014 , 4, 274	53	14
453	[Head and neck cancers in HIV patients]. 2014 , 101, 1030-3		0
452	Quel traitement (laryngectomie totale ou pr�servation laryng�) envisagerait un sp�cialiste otorhinolaryngologiste si l'on fait atteint d'un cancer du larynx de stade avanc�? 2014 , 131, 328-332		
451	Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments. 2014 , 41, 798-806		23
450	Factors affecting swallow outcome following treatment for advanced oral and oropharyngeal malignancies. 2014 , 36, 47-54		17
449	Tumour repopulation and the role of abortive division in squamous cell carcinomas during chemotherapy. 2014 , 47, 318-25		6
448	[Oral cavity cancer, an update on behalf of Intergroupe ORL]. 2014 , 101, 424-8		1
447	A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study. 2014 , 25, 970-5		6
446	Oropharyngeal squamous cell carcinoma treatment: current standards and future directions. 2014 , 26, 252-8		12
445	The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach. 2014 , 40, 178-89		32
444	Total laryngectomy or laryngeal preservation for advanced laryngeal cancer. Impact of the functional risk upon the patient's preferences. 2014 , 131, 93-7		20

443	Observational study designs for comparative effectiveness research: an alternative approach to close evidence gaps in head-and-neck cancer. 2014 , 88, 106-14		14
442	Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. <i>Oral Oncology</i> , 2014 , 50, 254-62	4.4	82
441	Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. <i>Radiotherapy and Oncology</i> , 2014 , 110, 91-7	5.3	71
440	Dose-dependent deterioration of swallowing function after induction chemotherapy and definitive chemoradiotherapy for laryngopharyngeal cancer. 2014 , 190, 192-8		12
439	Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial. 2014 , 190, 250-5		11
438	When is re-irradiation in head and neck squamous cell carcinoma not indicated?. 2014 , 271, 3107-9		7
437	Aktuelle Aspekte der radioonkologischen Behandlung lokal fortgeschrittener Kopf-Hals-Tumoren. 2014 , 20, 139-143		2
436	[Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension]. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2014 , 18, 1-6	1.3	4
435	Improving chemoradiation efficacy by PI3-K/AKT inhibition. 2014 , 40, 1182-91		30
434	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. 2014 , 25, 462-6		58
433	[Which choice would the radiation oncologist consider if facing an advanced stage laryngeal cancer?]. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2014 , 18, 649-54	1.3	1
432	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. <i>Oral Oncology</i> , 2014 , 50, 888-94	4.4	15
431	External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. 2014 , 110, 375-82		38
430	Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. <i>Oral Oncology</i> , 2014 , 50, 1041-8	4.4	88
429	Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. 2014 , 190, 823-31		37
428	Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?. 2014 , 190, 654-60		9
427	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. 2014 , 25, 694-699		27
426	Souhait et impact de l'information avant laryngectomie totale ou prservation larynge dans les cancers du larynx de stade avanc. 2014 , 131, 76-82		

425	Head and Neck Cancer in the Older Adult: Approaches in Evaluation and Management. 2014 , 3, 209-219		1
424	Otorhinolaryngologists' personal treatment preferences (total laryngectomy or laryngeal preservation) when faced with advanced stage laryngeal cancer. 2014 , 131, 339-343		4
423	25 year survival outcomes for squamous cell carcinomas of the head and neck: population-based outcomes from a Canadian province. <i>Oral Oncology</i> , 2014 , 50, 651-6	4.4	42
422	Cancer of the head and neck. 2014 , 158-183		
421	Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience. <i>Cancer Medicine</i> , 2015 , 4, 651-60	4.8	11
420	Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse. 2015 , 5, 16389		25
419	Regional recurrence of oropharyngeal cancer after definitive radiotherapy: a case control study. 2015 , 10, 117		2
418	Treatment of T3 laryngeal cancer in the Netherlands: a national survey. 2015 , 10, 134		4
417	Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. 2015 , 37, 1274-81		17
416	Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review. 2015 , 9, 1-7		14
415	Oropharyngeal squamous cell carcinoma in the veteran population: Association with traditional carcinogen exposure and poor clinical outcomes. 2015 , 37, 1246-53		22
414	Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer. 2015 , 2015, 612610		5
413	Sequential and Concurrent Chemoradiation: State of the Art. 2015 , 29, 1061-74		1
412	Aloin delivery on buccal mucosa: ex vivo studies and design of a new locoregional dosing system. 2015 , 41, 1541-7		17
411	Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. 2015 , 37, 134-50		77
410	Induction chemotherapy in squamous cell carcinoma of the head and neck: saved by the bell?. <i>Oral Oncology</i> , 2015 , 51, e5-7	4.4	2
409	The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF α -mediated in head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015 , 116, 495-503	5.3	32
408	The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015 , 117, 91-8	5.3	44

407	[Radioresistance parameters in head and neck cancers and methods to radiosensitize]. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015 , 19, 337-46; quiz 360-1, 363	1.3	5
406	Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. <i>Acta Oncologica</i> , 2015 , 54, 1001-7	3.2	67
405	Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis. 2015 , 121, 2083-9		42
404	Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck. 2015 , 15, 102		2
403	[Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: Principles, results and perspectives]. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015 , 19, 198-204; quiz 228-9, 233	1.3	0
402	An observational study of social control, mood, and self-efficacy in couples during treatment for head and neck cancer. 2015 , 30, 783-802		23
401	Organisation du parcours initial de soins en cancérologie des VADS (version courte) : organisation de la chimiothérapie en cancérologie des voies aéro-digestives supérieures. 2015 , 132, 196-200		
400	Reconstructive Oral and Maxillofacial Surgery. 2015 ,		
399	Organization of primary care pathway in head and neck oncology (short version): Organization of chemotherapy in head and neck oncology. 2015 , 132, 209-12		
398	Phase 2 Study of Docetaxel, Cisplatin, and Concurrent Radiation for Technically Resectable Stage III-IV Squamous Cell Carcinoma of the Head and Neck: In Regard to Inohara et al. 2015 , 93, 469-70		3
397	Radiation Therapy for Head and Neck Cancers. 2015 ,		4
396	Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma. 2015 , 37, 1650-9		7
395	A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). 2016 , 7, 7110-9		29
394	Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines. 2016 , 7, 35832-35842		24
393	Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study. <i>Current Oncology</i> , 2016 , 23, 266-72	2.8	13
392	Hypopharyngeal cancer: looking back, moving forward. <i>Current Oncology</i> , 2016 , 23, 221-2	2.8	9
391	The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung. 2016 , 7, 591		52
390	HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. 2016 , 8,		69

389	Neoadjuvant Systemic Chemotherapy in the Management of Extensive Eyelid Sebaceous Gland Carcinoma: A study of 10 Cases. 2016 , 32, 35-9		22
388	Adverse effect of smoking on prognosis in human papillomavirus-associated oropharyngeal carcinoma. 2016 , 38, 1780-1787		19
387	Predictors of severe long-term toxicity after re-irradiation for head and neck cancer. <i>Oral Oncology</i> , 2016 , 60, 32-40	4.4	22
386	High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. 2016 , 38 Suppl 1, E2041-8		23
385	Clinical outcomes in patients with T4 laryngeal cancer treated with primary radiotherapy versus primary laryngectomy. 2016 , 38 Suppl 1, E2035-40		20
384	Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, □ Docetaxel for Larynx Preservation. 2016 , 108,		59
383	Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. 2016 , 39, 27-31		45
382	A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN). 2016 , 39, 522-7		1
381	Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base. 2016 , 122, 1853-60		28
380	Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers. 2016 , 91 Suppl 1, 35-40		14
379	Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. 2016 , 12, CD010963		26
378	A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. 2016 , 1, 379-385		3
377	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). 2016 , 34, 575-83		6
376	Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab. 2016 , 78, 320-333		3
375	Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. 2016 , 16, 829		0
374	Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group. <i>Radiotherapy and Oncology</i> , 2016 , 118, 257-66	5.3	25
373	Future treatment directions for HPV-associated head and neck cancer based on radiobiological rationale and current clinical evidence. 2016 , 103, 27-36		16
372	Radiotherapy in head and neck cancer management: United Kingdom National Multidisciplinary Guidelines. 2016 , 130, S66-S67		13

371	Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. <i>Acta Oncologica</i> , 2016 , 55, 1091-1098	3.2	48
370	Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life. <i>Oral Oncology</i> , 2016 , 58, 21-6	4.4	9
369	Hypopharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. 2016 , 130, S104-S110		34
368	Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model. 2016 , 102, 101-10		9
367	Induction chemotherapy for head and neck cancer: is there still a role?. <i>Future Oncology</i> , 2016 , 12, 1595-608	6.08	2
366	Larynx Cancer. 2016 , 83-112		
365	Induction chemotherapy for squamous cell carcinomas of the oral cavity: A cumulative meta-analysis. <i>Oral Oncology</i> , 2016 , 61, 104-14	4.4	19
364	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016 , 120, 48-55	5.3	129
363	Therapeutic Ratio of Reirradiation with Cytotoxic Drugs and Other Response-Modifying Agents. 2016 , 47-73		
362	[Radiotherapy for oral cavity cancers]. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2016 , 20 Suppl, S116-25	1.3	4
361	Treatment of head and neck cancer in the elderly. 2016 , 17, 1903-21		11
360	Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. 2016 , 16, 689		25
359	Cancer of the Oral Cavity, Pharynx and Larynx. 2016 ,		
358	HNO Fragen und Antworten. 2016 ,		
357	Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer. 2016 , 1, 6		9
356	Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. 2016 , 122, 3529-3537		57
355	ACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck. 2016 , 38, 175-82		15
354	Functional swallowing outcomes following treatment for oropharyngeal carcinoma: a systematic review of the evidence comparing trans-oral surgery versus non-surgical management. 2016 , 41, 371-85		17

353	Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic. 2016 , 11, 55		26
352	Prediction of critical weight loss during radiation treatment in head and neck cancer patients is dependent on BMI. <i>Supportive Care in Cancer</i> , 2016 , 24, 2101-2109	3.9	29
351	Up-regulation of HB-EGF by the COX-2/PGE2 signaling associates with the cisplatin resistance and tumor recurrence of advanced HNSCC. <i>Oral Oncology</i> , 2016 , 56, 54-61	4.4	10
350	Trends in cancer of the head and neck in the elderly in Denmark, 1980-2012. <i>Acta Oncologica</i> , 2016 , 55 Suppl 1, 13-8	3.2	3
349	Chemotherapy in locally advanced head and neck squamous cell carcinoma. 2016 , 44, 10-6		18
348	Preliminary study of transoral robotic surgery for pharyngeal cancer in Japan. 2016 , 10, 11-7		14
347	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. 2016 , 100, 147-66		92
346	Unilateral and bilateral neck SIB for head and neck cancer patients : Intensity-modulated proton therapy, tomotherapy, and RapidArc. 2016 , 192, 232-9		16
345	Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. 2016 , 91, 386-96		543
344	EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?. 2016 , 99, 170-9		12
343	Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients: Differences in dose distributions and potential implications for clinical practice. 2016 , 192, 17-24		12
342	Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. 2016 , 273, 2877-94		18
341	Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials. 2017 , 44, 18-25		20
340	Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). 2017 , 72, 192-199		14
339	Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy. <i>Oral Oncology</i> , 2017 , 67, 10-16	4.4	5
338	Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. 2017 , 12, 45		23
337	An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma. 2017 , 23, 3769-3780		23
336	Reirradiation of head and neck cancer: Long-term disease control and toxicity. 2017 , 39, 1122-1130		31

335	Survey of return to work of head and neck cancer survivors: A report from a tertiary cancer center in India. 2017 , 39, 893-899			17
334	Swallowing after transoral surgery for oropharyngeal cancer: comparison with primary chemoradiotherapy outcomes. 2017 , 25, 101-107			3
333	Oropharyngeal Cancer. 2017 , 202-226			
332	A prospective evaluation of short-term dysphagia after transoral robotic surgery for squamous cell carcinoma of the oropharynx. 2017 , 123, 3132-3140			25
331	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. 2017 , 28, 1605-1611			324
330	[Recent Developments Towards Molecularly Targeted Therapy of Head and Neck Cancer]. 2017 , 96, 185-198			
329	An update on larynx cancer. 2017 , 67, 31-50			274
328	Does chemoselection open the door for immunotherapy?. 2017 , 28, 1697-1699			
327	Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. <i>Oral Oncology</i> , 2017 , 71, 61-66	4-4		8
326	Neck dissection for unknown cancer of the head and neck in the era of chemoradiation. 2017 , 38, 588-592			12
325	Nutritional changes in patients with locally advanced head and neck cancer during treatment. <i>Oral Oncology</i> , 2017 , 71, 67-74	4-4		41
324	Impact on quality of life of IMRT versus 3-D conformal radiation therapy in head and neck cancer patients: A case control study. 2017 , 2, 346-353			14
323	Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs. 2017 , 127, 2565-2569			20
322	[Prognostic factors for head and neck cancer reirradiation: A systematic review]. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2017 , 21, 316-338	1-3		2
321	Results of total laryngectomy as treatment for locally advanced hypopharyngeal cancer. 2017 , 68, 328-335			5
320	Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review. 2017 , 46, 29			29
319	Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis. 2017 , 39, 1113-1121			10
318	Recurrence patterns after a decreased dose of 40Gy to the elective treated neck in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017 , 123, 419-423	5-3		18

317	Comprehensive Overview: Definitive Radiotherapy and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer. 2017 , 151-176		3
316	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. 2017 , 3, 220-226		48
315	Critical Issues in Head and Neck Oncology. 2017 ,		
314	Pros and Cons of Endoscopic Surgery. 2017 , 111-139		
313	The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. 2017 , 90, 20170442		17
312	Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study. <i>British Journal of Cancer</i> , 2017 , 117, 1105-1112	8.7	6
311	Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity. <i>Radiotherapy and Oncology</i> , 2017 , 124, 220-224	5.3	7
310	Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters. <i>Radiotherapy and Oncology</i> , 2017 , 124, 256-262	5.3	32
309	Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. 2017 , 39, 2329-2349		15
308	Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis. 2017 , 14, 6103-6108		1
307	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. 2017 , 7, 28-35		12
306	Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck. 2017 , 7, 151-157		14
305	Survival after refusal of surgical treatment for locally advanced laryngeal cancer. <i>Oral Oncology</i> , 2017 , 71, 34-40	4.4	11
304	Perioperative changes in osteopontin and TGF β plasma levels and their prognostic impact for radiotherapy in head and neck cancer. 2017 , 17, 6		2
303	Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12-week guided home-based program. 2017 , 274, 1129-1138		32
302	A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. 2017 , 123, 600-608		34
301	Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. <i>Radiotherapy and Oncology</i> , 2017 , 122, 171-177	5.3	38
300	American Brachytherapy Society Task Group Report: Combined external beam irradiation and interstitial brachytherapy for base of tongue tumors and other head and neck sites in the era of new technologies. 2017 , 16, 44-58		17

299	Radiotherapy induced dermatitis is a strong predictor for late fibrosis in head and neck cancer. The development of a predictive model for late fibrosis. <i>Radiotherapy and Oncology</i> , 2017 , 122, 212-216	5.3	15
298	Extrapolation of Survival Curves from Cancer Trials Using External Information. 2017 , 37, 353-366		25
297	Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥ 70 years. 2017 , 8, 50-55		21
296	HPV Infection in Head and Neck Cancer. 2017 ,		3
295	The Role of Conventional Surgery in Oropharyngeal Cancer. 2017 , 206, 185-195		1
294	Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy. 2017 , 127, 1791-1796		5
293	Results of Total Laryngectomy as Treatment for Locally Advanced Hypopharyngeal Cancer. 2017 , 68, 328-335		
292	?????????????????????????????. 2017 , 120, 248-251		1
291	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥ 5 years old. 2017 , 12, 150		18
290	Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis. 2017 , 8, 2587-2594		6
289	Systemic therapy in the curative treatment of head-and-neck squamous cell cancer: Cancer Care Ontario clinical practice guideline. <i>Current Oncology</i> , 2017 , 24, e157-e162	2.8	4
288	Multiparametric magnetic resonance imaging in mucosal primary head and neck cancer: a prospective imaging biomarker study. 2017 , 17, 475		5
287	Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow. 2017 , 12, 129		4
286	Outcomes for patients with head and neck squamous cell carcinoma presenting with N3 nodal disease. 2017 , 2,		5
285	The Team Approach in the Management of Head and Neck Cancer. 2017 , 285-291		
284	Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma. <i>Oral Oncology</i> , 2018 , 79, 9-14	4.4	5
283	Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial. <i>Oral Oncology</i> , 2018 , 78, 108-113	4.4	14
282	Defining the low-risk salvage laryngectomy-A single-center retrospective analysis of pharyngocutaneous fistula. 2018 , 3, 115-120		2

281	Head and neck cancer in Hong Kong. 2018 , 48, 13-21		5
280	Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck. 2018 , 29, 998-1003		13
279	Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses. <i>Supportive Care in Cancer</i> , 2018 , 26, 2417-2423	3.9	31
278	Evaluation of treatment outcomes in patients with supraglottic laryngeal cancer in Ontario, Canada: A population-based study. 2018 , 40, 1024-1033		4
277	. 2018 , 2, 33-40		7
276	Radiotherapeutic factors affecting the incidence of developing hypothyroidism after radiotherapy for head and neck squamous cell cancer. 2018 , 30, 33-38		2
275	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. <i>Oral Oncology</i> , 2018 , 79, 1-8	4.4	2
274	Using primary tumor volumetry to predict treatment outcome for patients with oropharyngeal cancer who were treated with definitive chemoradiotherapy. 2018 , 14, e21-e28		1
273	Radiation Therapy for Oral Cavity and Oropharyngeal Cancers. 2018 , 62, 99-109		14
272	Organ-Sparing in Radiotherapy for Head-and-Neck Cancer: Improving Quality of Life. 2018 , 28, 46-52		27
271	Nivolumab in recurrent/metastatic head and neck cancers. <i>Future Oncology</i> , 2018 , 14, 603-609	3.6	3
270	Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. 2018 , 275, 181-189		65
269	Individualized outcome prognostication for patients with laryngeal cancer. 2018 , 124, 706-716		8
268	In Regard to Sher et al. 2018 , 8, 66-67		
267	Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. 2018 , 36, 1269-1271		2
266	Outcome of Concurrent Chemoradiotherapy and Radiotherapy Alone Following Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck. 2018 , 44, 93-97		1
265	Quality of life in patients with larynx cancer in Latin America: Comparison between laryngectomy and organ preservation protocols. 2018 , 97, 83-90		3
264	Reinke edema. 2018 , 97, E49-E50		3

263	Impact of Time Factors on Outcome in Patients with Head and Neck Cancer Treated with Definitive Radio(Chemo)Therapy. 2017 , 31, 949-955		5
262	De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma. 2018 , 12, CD012939		20
261	Induction Chemotherapy: Does It Have a Place in Oral Cavity Cancer?. 2018 , 99-103		
260	Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. 2018 , 12, CD006205		13
259	Feasibility single-arm study of a medical device containing and combined with chemotherapy in head and neck cancer patients. 2018 , 10, 5433-5438		0
258	Head and Neck Cancer: Improving Patient-Reported Outcome Measures for Clinical Practice. 2018 , 19, 59		8
257	From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. <i>Oral Oncology</i> , 2018 , 86, 200-205	4.4	6
256	7 Role of Radiotherapy in the Treatment of Skin Malignancies. 2018 ,		
255	IMRT - Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. <i>Oral Oncology</i> , 2018 , 86, 91-99	4.4	5
254	Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status. <i>Cancer Reports</i> , 2018 , 1, e1001 ¹⁻⁵		1
253	Modulated radiotherapy for head and neck carcinomas: an outcome study. 2018 , 17, 384-389		
252	Two Sides of the Same Coin: Head and Neck Cancer Treatment De-Intensification and Intensification with Induction Chemotherapy. 2018 , 102, 1-4		2
251	De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma. 2018 ,		2
250	Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset. <i>Oral Oncology</i> , 2018 , 84, 12-19	4.4	10
249	A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma. 2018 , 8, 12675		7
248	Cancers of the Oral Cavity: Diagnosis and Treatment. 2018 ,		
247	Unilateral cochlea sparing in locoregionally advanced head and neck cancer: a planning study. 2018 , 194, 1124-1131		1
246	Radiation Therapy. 2018 , 268-290		1

245	Chemotherapy. 2018 , 291-313		
244	Early Floor of Mouth Cancer. 2018 , 420-427		
243	Lip Cancer. 2018 , 608-625		1
242	Advanced HPV-Related Oropharynx Cancer. 2018 , 677-699		
241	Advanced HPV-Unrelated Pharynx Cancer. 2018 , 700-760		
240	Electrochemotherapy with cisplatin or bleomycin in head and neck squamous cell carcinoma: Improved effectiveness of cisplatin in HPV-positive tumors. 2018 , 123, 248-254		13
239	Evidence-Based Practice: Management of Glottic Cancer. 2018 , 163-173		
238	Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. 2019 , 20, 1349-1359		164
237	Patterns of utilization and comparative efficacy of altered fractionation and concurrent chemoradiation for treatment for T2N0M0 glottic carcinoma. 2019 , 8, 267-278		
236	Laryngo-esophageal dysfunction free survival and propensity score matched analysis comparing organ preservation and total laryngectomy in hypopharynx cancer. <i>Oral Oncology</i> , 2019 , 95, 143-149	4.4	2
235	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. <i>Oral Oncology</i> , 2019 , 95, 106-114	4.4	11
234	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. 2019 , 118, 112-120		5
233	Definitive radiotherapy vs. postoperative radiotherapy for lower gingival carcinomas of the mandible : A single-center report about outcome and toxicity. 2019 , 195, 819-829		6
232	Advances in Diagnosis and Multidisciplinary Management of Oropharyngeal Squamous Cell Carcinoma: State of the Art. 2019 , 39, 2055-2068		7
231	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. 2019 , 394, 1915-1928		839
230	[Laryngectomy-still state of the art?]. 2019 , 67, 955-976		0
229	Astonishing Evolution in Oropharyngeal Cancer with Immunotherapy: A Case Report. 2019 , 37, 531-534		
228	The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2019 , 8, 5969-5978	4.8	17

227	Partial pharyngolaryngectomy with infrahyoid flap: Our experience. 2019 , 40, 102271		1
226	A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2019 , 58, 1495-1501	3-2	14
225	Exploring Radiation Response in Two Head and Neck Squamous Carcinoma Cell Lines Through Metabolic Profiling. <i>Frontiers in Oncology</i> , 2019 , 9, 825	5-3	8
224	Addition of chemotherapy to hyperfractionated radiotherapy in advanced head and neck cancer-a meta-analysis. 2019 , 195, 1041-1049		11
223	Head and Neck Cancers. 2019 , 133-196		
222	Prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma treated by intra-arterial infusion chemotherapy concurrent with radiotherapy. 2019 , 41, 1777-1784		6
221	Ten-year outcome of curative "exclusive" chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response. 2019 , 41, 2190-2196		6
220	Absolute Clinical Radiation Oncology Review. 2019 ,		2
219	The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. 2019 , 41, 2271-2276		6
218	[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019 , 23, 273-280	1-3	7
217	Current concepts and novel techniques in the prosthodontic management of head and neck cancer patients. 2019 , 226, 725-737		5
216	The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective. 2019 , 17, 47-50		13
215	A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. 2019 , 125, 3184-3197		42
214	Current Role of Surgery in the Management of Oropharyngeal Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 388	5-3	25
213	The changing therapeutic landscape of head and neck cancer. 2019 , 16, 669-683		195
212	Functional Organ Preservation Surgery in Head and Neck Cancer: Transoral Robotic Surgery and Beyond. <i>Frontiers in Oncology</i> , 2019 , 9, 293	5-3	15
211	Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?. 2019 , 39, 364-372		24
210	Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. 2019 , 104, 365-373		16

209	Undertreatment of women with locoregionally advanced head and neck cancer. 2019 , 125, 3033-3039		16
208	Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. 2019 , 10, 698		32
207	Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response. <i>Radiotherapy and Oncology</i> , 2019 , 135, 1-12	5.3	14
206	Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities. A systematic review. <i>Oral Oncology</i> , 2019 , 93, 21-28	4.4	32
205	Outcomes of Tumour Control from Primary Treatment of Hypopharyngeal Cancer. 2019 , 83, 90-108		2
204	Emerging patient-specific treatment modalities in head and neck cancer - a systematic review. 2019 , 28, 365-376		2
203	A Hidden Epidemic of "Intermediate Risk" Oropharynx Cancer. 2019 , 4, 617-623		5
202	14 Carcinoma of the Hypopharynx. 2019 ,		
201	Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines. 2019 , 14, 214		10
200	Demographic predictors of head and neck cancer survival differ in the elderly. 2019 , 129, 146-153		8
199	The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. 2018 , 36, 8		13
198	Impact of age on elderly patients with oral cancer. 2019 , 276, 223-231		3
197	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. 2019 , 393, 40-50		546
196	Twist and E-cadherin deregulation might predict poor prognosis in lower lip squamous cell carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2019 , 127, 318-329	2	6
195	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. <i>Oral Oncology</i> , 2019 , 89, 72-78	4.4	16
194	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. 2019 , 393, 156-167		674
193	An Imager's Guide to Perineural Tumor Spread in Head and Neck Cancers: Radiologic Footprints on F-FDG PET, with CT and MRI Correlates. 2019 , 60, 304-311		17
192	Treatment challenges in and outside a network setting: Head and neck cancers. 2019 , 45, 40-45		21

191	Disease-induced and treatment-induced alterations in body composition in locally advanced head and neck squamous cell carcinoma. 2020 , 11, 145-159		17
190	Comparison between hypo-fractionated dose-escalated volumetric modulated arc therapy and conventional concurrent chemo-radiation in locally advanced head and neck cancer: a pilot study. 2020 , 19, 132-138		1
189	Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". 2020 , 15, 7		8
188	Head and Neck Cancer. 2020 , 382, 60-72		386
187	Cancer of the Head and Neck. 2020 , 999-1033.e7		0
186	Prediction model for tube feeding dependency during chemoradiotherapy for at least four weeks in head and neck cancer patients: A tool for prophylactic gastrostomy decision making. 2020 , 39, 2600-2608		7
185	Alterations in genetic pathways following radiotherapy for head and neck cancer. 2020 , 42, 312-320		3
184	Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial. 2020 , 47, 1046-1055		24
183	Esophageal Cancer. 2020 ,		0
182	Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020 , 146, 106-112	3.9	9
181	CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. 2020 , 12,		2
180	[Concurrent chemoradiotherapy for head neck cancers. Should organs at risk dose constraints be revisited?]. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020 , 24, 586-593	1.3	2
179	Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
178	Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2020 , 31, 1462-1475		100
177	Pairing a prognostic target with potential therapeutic strategy for head and neck cancer. <i>Oral Oncology</i> , 2020 , 111, 105035	4.4	2
176	Cancro dell'orofaringe. 2020 , 19, 1-17		
175	Influence of smoking history on the perception of radiation-induced dysgeusia/hypogeusia in patients with head and neck cancer. 2021 , 278, 2993-3001		0
174	Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. 2020 , 7, 600612		4

173	The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review. <i>Frontiers in Oncology</i> , 2020 , 10, 1402	5-3	4
172	Outcome in patients with isolated regional recurrence after primary radiotherapy for head and neck cancer. 2020 , 42, 3161-3170		6
171	The Role of Palliative Radiotherapy in the Treatment of Spinal Bone Metastases from Head and Neck Tumors-A Multicenter Analysis of a Rare Event. 2020 , 12,		2
170	Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting. <i>Frontiers in Oncology</i> , 2020 , 10, 1260	5-3	6
169	C�ncer de hipofaringe. 2020 , 49, 1-20		
168	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. 2020 , 20, 912		8
167	Deeskalation der multimodalen Therapie von Kopf-Hals-Karzinomen. 2020 , 15, 346-361		
166	Missed radiation therapy sessions in first three weeks predict distant metastasis and less favorable outcomes in surgically treated patients with oral cavity squamous cell carcinoma. 2020 , 15, 194		2
165	Subjective functional outcomes in oropharyngeal cancer treated with induction chemotherapy using the MD Anderson Symptom Inventory (MDASI). 2020 , 5, 1104-1109		1
164	Change in Age at Diagnosis of Oropharyngeal Cancer in the United States, 1975-2016. 2020 , 12,		3
163	Transoral Robotic Surgery and De-escalation of Cancer Treatment. 2020 , 53, 981-994		1
162	C�ncer de orofaringe. 2020 , 49, 1-18		
161	Comparing national practice versus standard guidelines for the use of adjuvant treatment following robotic surgery for oropharyngeal squamous cell carcinoma. 2020 , 42, 2602-2606		6
160	Evaluation of Contrast-Enhanced Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) in the Detection of Retropharyngeal Lymph Node Metastases in Nasopharyngeal Carcinoma Patients. 2020 , 12, 1733-1739		2
159	Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial. 2020 , 20, 125		26
158	Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPV-negative experimental pharyngeal squamous cell carcinoma. 2020 , 10, 1563		5
157	CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. 2020 , 10, 243		4
156	Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives?. 2020 , 32, 196-202		2

155	Carcinomas of the lacrimal drainage system. 2020 , 65, 691-707		9
154	Combining Chk1/2 inhibition with radiation in head and neck cancer. 2020 , 301-316		
153	Comparison of Current Surgical and Non-Surgical Treatment Strategies for Early and Locally Advanced Stage Glottic Laryngeal Cancer and Their Outcome. 2020 , 12,		15
152	Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life. 2021 , 30, 117-127		1
151	Incidence of radiation induced sarcoma attributable to radiotherapy in adults: A retrospective cohort study in the SEER cancer registries across 17 primary tumor sites. 2021 , 70, 101857		7
150	Institutional financial toxicity of failure to adhere to treatment guidelines for head and neck squamous cell carcinoma. 2021 , 43, 816-824		0
149	Oropharyngeal cancer and osteoradionecrosis in a novel radiation era: a single institution analysis. 2021 , 14, 113-121		8
148	Systematic review of postoperative therapy for resected squamous cell carcinoma of the head and neck: Executive summary of the American Radium Society appropriate use criteria. 2021 , 43, 367-391		4
147	Reprint of "Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up". <i>Oral Oncology</i> , 2021 , 113, 105042	4-4	3
146	Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial. 2021 , 62, 471-478		7
145	[Functional outcome after transmandibular resection and primary chemoradiation in advanced oropharyngeal squamous cell carcinoma]. 2021 , 69, 110-121		
144	Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection. 2021 , 131, E846-E850		1
143	Evaluation of survival of patients with locally advanced head and neck cancer treated in a single center. 2021 , 87, 3-10		4
142	Evaluation of Optimal Post-Injection Timing of Hypoxic Imaging with F-Fluoromisonidazole-PET/CT. 2021 , 23, 597-603		0
141	Radioterapia de los cánceres otorrinolaringológicos. 2021 , 50, 1-11		
140	Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer. 2021 , 35, 411-415		1
139	Is there a Role for Neoadjuvant Targeted Therapy and Immunotherapy?. 2021 , 193-203		
138	Preoperative predictors of dysphagia after transoral surgery. 2021 , 26, 835-840		1

137	New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era. 2021 , 10,	2
136	Evaluation of pharyngeal swallowing pressure using high-resolution manometry during transoral surgery for oropharyngeal cancer. 2021 , 135, 153-158	1
135	Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness. 2021 , 10, 20	6
134	Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation. 2021 , 14, 929-936	0
133	Personalized automation of treatment planning in head-neck cancer: A step forward for quality in radiation therapy?. 2021 , 82, 7-16	5
132	Impact of different image guidance schedules in head and neck irradiation: A retrospective analysis. 2021 , 5, 34-42	
131	Cancro dell'ipofaringe. 2021 , 20, 1-19	
130	Retrospective analysis of outcome and toxicity after postoperative radiotherapy in patients with squamous cell carcinoma of the lip. 2021 , 300891621996805	0
129	The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry. 2021 , 127, 2453-2464	2
128	Radioterapia dei cancri oto-rino-laringoiatrici. 2021 , 20, 1-10	
127	Early Clinical Outcomes of Intensity Modulated Radiation Therapy/Intensity Modulated Proton Therapy Combination in Comparison with Intensity Modulated Radiation Therapy Alone in Oropharynx Cancer Patients. 2021 , 13,	2
126	Total Laryngectomy-Still Cutting-Edge?. 2021 , 13,	1
125	Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers. 2021 , 21, 360	4
124	Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. 2021 , 502, 180-188	10
123	Post-operative outcomes of different surgical approaches to oropharyngeal squamous cell cancer: a case-matched study. 2021 , 135, 348-354	2
122	Treatment outcomes in patients with supraglottic laryngeal cancer: a single centre study. 2021 , 141, 649-655	1
121	We have met the Enemy and (S)He is Us. 2021 , 43, 2685-2687	
120	Extranodal extension in head and neck squamous cell cancer: is there a role for further stratification?. 2021 , 59, 567-572	1

119	Mechanisms of Ferroptosis and Application to Head and Neck Squamous Cell Carcinoma Treatments. 2021 , 40, 720-732	3
118	Artificial Intelligence and Radiomics in Head and Neck Cancer Care: Opportunities, Mechanics, and Challenges. 2021 , 41, 1-11	2
117	Retail atmospherics effect on store performance and personalised shopper behaviour: a cognitive computing approach. 2021 , ahead-of-print,	1
116	Prediction of Radiation-Related Dental Caries Through PyRadiomics Features and Artificial Neural Network on Panoramic Radiography. 2021 , 34, 1237-1248	2
115	Current status of systemic therapy in head and neck cancer. 2021 , 1-16	0
114	Comparing the Effectiveness of Non-Surgical and Surgical Treatment Modalities in the Management of Oropharyngeal Carcinoma: A Systematic Review and Meta-Analysis. 2021 , 2, 244-252	
113	Efficacy of the pretreatment geriatric nutritional risk index for predicting severe adverse events in patients with head and neck cancer treated with chemoradiotherapy: Efficacy of the pretreatment Geriatric Nutritional Risk Index for predicting severe adverse events. 2021 ,	0
112	Role of Organ Preservation in Locally Advanced Hypopharyngeal Carcinoma.	
111	Therapeutic strategies for systemic therapies of human papillomavirus-related oropharyngeal cancer. 2021 , 124, 952-961	1
110	[The role of chemoradiotherapy in curative treatment of head and neck cancer]. 2021 ,	0
109	Treatment Strategies in Head and Neck Cancers. 2020 , 273-294	1
108	Assessment of DNA damage by 53PB1 and pKu70 detection in peripheral blood lymphocytes by immunofluorescence and high-resolution transmission electron microscopy. 2020 , 196, 821-833	4
107	Concomitant chemotherapy increases radiotherapy-mediated DNA-damage in peripheral blood lymphocytes.	1
106	Advances in the management of squamous cell carcinoma of the head and neck. 2014 , 6, 44	61
105	Locally advanced head and neck cancer. 2013 , 237-44	4
104	Oral Cancer: Prevention, Early Detection, and Treatment. 2015 , 85-99	33
103	Effects of Neoadjuvant Chemotherapy and Radiotherapy on Flap Perfusion in a Novel Mouse Model Using Standard Clinical Assessment and Near-Infrared Fluorescence Angiography. 038-042	1
102	Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. 2017 , 8, 3870-3880	30

101	Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells. 2016 , 7, 23542-51		16
100	Prognostic role of diffusion weighted and dynamic contrast-enhanced MRI in loco-regionally advanced head and neck cancer treated with concomitant chemoradiotherapy. <i>Radiology and Oncology</i> , 2019 , 53, 39-48	3.8	6
99	Pulsed low dose-rate irradiation response in isogenic HNSCC cell lines with different radiosensitivity. <i>Radiology and Oncology</i> , 2020 , 54, 168-179	3.8	4
98	Indian clinical practice consensus guidelines for the management of oropharyngeal cancer. 2020 , 57, S12-S15		2
97	Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. 2016 , 143, 145-59		10
96	Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. <i>Journal of Oral & Maxillofacial Research</i> , 2013 , 4, e1	2.1	17
95	Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches. <i>World Journal of Clinical Oncology</i> , 2016 , 7, 15-26	2.5	13
94	Patterns of Distant Failure and Second Primary Cancers in Patients with Oropharyngeal Squamous Cell Carcinoma: Implications for Surveillance Methodology. <i>Journal of Cancer Research Updates</i> , 2014 , 3, 151-161	1	2
93	A case of primary tracheal squamous cell carcinoma arising from malignant transformation of recurrent respiratory papillomatosis, with a complete response to concurrent chemoradiotherapy. <i>SAGE Open Medical Case Reports</i> , 2021 , 9, 2050313X211054623	0.7	0
92	Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer. <i>Onco</i> , 2021 , 1, 83-94		0
91	Pretreatment Systemic Immune-Inflammation Index Predict Needs for Teeth Extractions for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. <i>Therapeutics and Clinical Risk Management</i> , 2021 , 17, 1113-1121	2.9	0
90	Chemotherapy and molecularly targeted therapies for previously untreated SCCHN. 2013 , 80-99		
89	Cancer of the Head and Neck. 2014 , 1037-1070.e6		
88	Head and neck cancers: Safely preserving the talk. <i>South Asian Journal of Cancer</i> , 2014 , 3, 143-4	0.7	
87	Hypopharyngeal Cancer. 2015 , 141-159		
86	Metastatic Cancer in Neck Node with Occult Primary. 2015 , 201-219		
85	Functional Implant-Supported Dental Rehabilitation in Oncologic Patients. 2015 , 163-202		1
84	E28 Literaturhinweise und Internetadressen. 2015 , e1-e79		

83	The Multidisciplinary Management of Early Stage Cervical Esophageal Cancer. 2015 , 173-185		
82	Head and Neck Squamous Cell Carcinoma in Iran: Clinico-Pathological and Treatment-Related Factors Influencing Survival. <i>Iranian Journal of Cancer Prevention</i> , 2015 , 8, e3842		4
81	Onkologie. 2016 , 177-212		
80	Current and Emerging Role of Chemotherapy in Oral Cancer. 2017 , 127-146		1
79	Malignome des Kopf- und Halsbereichs. 2017 , 581-604		
78	Accelerated Fractionation Radiotherapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Journal of Cancer Prevention & Current Research</i> , 2017 , 8,	1.3	
77	Oncology Gold Standard practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck. <i>South Asian Journal of Cancer</i> , 2017 , 6, 154-160	0.7	2
76	Treatment Paradigms in HPV-Associated SCCHN. <i>Current Cancer Research</i> , 2018 , 585-615	0.2	
75	Permanent Interstitial Brachytherapy for Previously Irradiated Head and Neck Cancer. <i>Cureus</i> , 2018 , 10, e2517	1.2	5
74	Role of Oral Glutamine in Prevention and Treatment of Oral Mucositis in Head and Neck Cancer Patients Receiving Chemoradiation. <i>Journal of Analytical Oncology</i> , 8, 5-9		
73	Squamous Cell Carcinoma of the Head and Neck. 2019 , 697-720		1
72	Human Papillomavirus-Related Head and Neck Cancer. 2019 , 45-68		
71	The Multidisciplinary Management of Early-Stage Cervical Esophageal Cancer. 2020 , 221-236		
70	Assessment of Treatment Response and Survival in Patients Diagnosed with Locally Advanced Head and Neck Cancer and Treated with Chemoradiotherapy As Part of An Organ-Preservation Treatment Protocol. <i>Sakarya Medical Journal</i> ,	0.1	
69	Locally Advanced Oral Tongue Cancer: Is Organ Preservation a Safe Option in Resource-Limited High-Volume Setting?. <i>Annals of Maxillofacial Surgery</i> , 2020 , 10, 158-163	1	0
68	Integrated Data Analysis Implicates PLAU, SERPINE1, SPP1, and MMP1 as Prognostic Factors in Head and Neck Squamous Cell Carcinoma. <i>Journal of Postgraduate Medicine Education and Research</i> , 2021 , 55, 160-170	0.1	
67	Principles of Management of Head and Neck Cancers. 2021 , 409-425		
66	Combining radiation and chemotherapy to improve the therapeutic ratio. 2020 , 49-63		

65	Authors' reply to Kuriakose et al., Mallick et al., and Chaukar et al.. <i>Cancer Research Statistics and Treatment</i> , 2020 , 3, 390	0.3	
64	Cancer des voies aëodigestiveset supërieures. 2020 , 178-189.e4		
63	Treatment of hypopharyngeal carcinoma complicated with diabetic nephropathy: a case report and literature review.. <i>Translational Cancer Research</i> , 2020 , 9, 2040-2044	0.3	
62	Selective inhibition of EGFR downstream signaling reverses the irradiation-enhanced migration of HNSCC cells. <i>American Journal of Cancer Research</i> , 2015 , 5, 2660-72	4.4	6
61	Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. <i>American Journal of Cancer Research</i> , 2020 , 10, 1821-1826	4.4	2
60	Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy. <i>Ecancermedicalscience</i> , 2020 , 14, 1095	2.7	1
59	Differential molecular response of larynx cancer cell lines to combined VPA/CDDP treatment. <i>American Journal of Cancer Research</i> , 2021 , 11, 2821-2837	4.4	1
58	Tumoren im Kopf-Hals-Bereich. 2022 , 230-241		
57	Definitive radiotherapy for squamous cell carcinoma of the oral cavity: a single-institution experience. <i>Radiology and Oncology</i> , 2021 , 55, 467-473	3.8	
56	Generation of Non-Nucleotide CD73 Inhibitors Using a Molecular Docking and 3D-QSAR Approach. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
55	Patterns-of-Care Analysis for Radiotherapy of Elderly Head-and-Neck Cancer Patients: A Trinational Survey in Germany, Austria and Switzerland.. <i>Frontiers in Oncology</i> , 2021 , 11, 723716	5.3	2
54	Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy. <i>Ecancermedicalscience</i> , 2020 , 14, 1095	2.7	1
53	Evaluation of the prevalence of metachronous second primary malignancies in hypopharyngeal carcinoma and their effect on outcomes.. <i>Cancer Medicine</i> , 2022 ,	4.8	1
52	A Techno-Business Platform to Improve Customer Experience Following the Brand Crisis Recovery: A B2B Perspective.. <i>Information Systems Frontiers</i> , 2022 , 1-25	4	1
51	A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis.. <i>British Journal of Cancer</i> , 2022 ,	8.7	0
50	Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register.. <i>Acta Oncologica</i> , 2022 , 1-8	3.2	0
49	Radiotherapy for oral cavity cancers.. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021 , 26, 189-189	1.3	0
48	Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III 'study design.. <i>Future Oncology</i> , 2022 ,	3.6	2

47	Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma.. <i>JAMA Network Open</i> , 2022 , 5, e220165	10.4	1
46	Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment.. <i>Frontiers in Oncology</i> , 2022 , 12, 781348	5.3	0
45	Kurative Radiochemotherapie von Kopf-Hals-Tumoren. <i>Tumor Diagnostik Und Therapie</i> , 2022 , 43, 120-132.	2.1	
44	Tooth extractions prior to chemoradiation or bioradiation are associated with weight loss during treatment for locally advanced oropharyngeal cancer.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	0
43	Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.. <i>Oral Oncology</i> , 2022 , 127, 105772	4.4	0
42	Expression of DNA-damage response and repair genes after exposure to DNA-damaging agents in isogenic head and neck cells with altered radiosensitivity.. <i>Radiology and Oncology</i> , 2022 ,	3.8	1
41	Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis.. <i>Clinical Oncology</i> , 2022 ,	2.8	0
40	Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O.. <i>Acta Otorhinolaryngologica Italica</i> , 2022 ,	2.8	
39	Survival rates of dental implants in patients with head and neck pathologies: 12-year single-operator study.. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021 ,	2	
38	A comparative study of planning and dosimetry in locally advanced head-and-neck cancer: sequential versus simultaneous integrated boost methods in intensity-modulated radiotherapy. <i>Journal of Radiation and Cancer Research</i> , 2022 ,	0.3	
37	PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022 , 1	5.1	0
36	Image_1.TIFF. 2019 ,		
35	Table_1.DOCX. 2019 ,		
34	Image_1.pdf. 2020 ,		
33	Data_Sheet_1.docx. 2020 ,		
32	Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.. <i>Frontiers in Oncology</i> , 2022 , 12, 868490	5.3	
31	Cost-effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer.. <i>Journal of Comparative Effectiveness Research</i> , 2022 ,	2.1	
30	Comparison of Patients With Head and Neck Cancer in Randomized Clinical Trials and Clinical Practice: A Systematic Review.. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022 ,	3.9	0

29	The COMPLETE trial: Holistic early response assessment for oropharyngeal cancer patients; Protocol for an observational study.. <i>BMJ Open</i> , 2022 , 12, e059345	3	
28	The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2022 , 130, 105907	4.4	
27	De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Where Are We Now?. <i>Current Oncology</i> , 2022 , 29, 3668-3697	2.8	1
26	Timing of radiotherapy and chemotherapy start for patients treated with definitive concurrent chemoradiation for head and neck cancer. <i>Acta Oncologica</i> , 1-7	3.2	
25	18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization. <i>Frontiers in Oncology</i> , 12,	5.3	0
24	Treatment outcomes of standard (high dose) cisplatin and non-standard chemotherapy for locally advanced head and neck cancer. <i>Cancer Reports</i> ,	1.5	
23	Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary result of a randomized phase 2 trial.		
22	Biomarkers of radioresistance in head and neck squamous cell carcinomas. 1-11		1
21	Current Evidence of a Deintensification Strategy for Patients with HPV-Related Oropharyngeal Cancer. 2022 , 14, 3969		1
20	De-intensification Strategies for Head and Neck Cancer. 2022 , 1-12		0
19	Cáceres otorrinolaringológicos: conducta práctica y tratamiento. 2022 ,		0
18	A 13-Year Single Institutional Experience with Definitive Radiotherapy in Hypopharyngeal Cancer. 2017 , 46, 32-36		1
17	Long term outcome and late toxicity Of SIB-IMRT in definitive management of head and neck cancers in patients not suitable for chemo-radiotherapy. 2022 , 0		0
16	Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer.		1
15	Oropharyngeal and Hypopharyngeal Tumours and Their Treatment. 2022 , 147-167		0
14	Treatment options for resectable hypopharyngeal squamous cell carcinoma: A systematic review and meta-analysis of randomized controlled trials. 2022 , 17, e0277460		1
13	Role of Post-Treatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients Receiving Definitive Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinomas. 2022 , 65, 697-704		0
12	Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial. 2022 , 22,		0

- 11 Prediction of extranodal extension in oropharyngeal cancer patients and carcinoma of unknown primary: value of metabolic tumor imaging with hybrid PET compared with MRI and CT. ○
- 10 Treatment outcomes and cost comparisons for older adults with T4 laryngeal squamous cell cancer. ○
- 9 Oropharynx und Larynx. **2022**, 171-187 ○
- 8 Medikamentöse Tumorthherapie des Äteren Menschen. **2022**, 297-315 ○
- 7 Oral health related quality of life of oral cancer patients treated with radiotherapy alone or with chemotherapy in a tertiary referral centre in Sri Lanka. **2023**, 23, ○
- 6 Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma. **2023**, 138, 106310 ○
- 5 Applying a nomogram based on preoperative CT to predict early recurrence of laryngeal squamous cell carcinoma after surgery. **2023**, 1-18 ○
- 4 Management of Recurrent HPV-Positive Oropharyngeal Squamous Cell Carcinoma: a Contemporary Review. **2023**, 25, 501-510 ○
- 3 Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma. **2023**, 1-10 ○
- 2 Clinical and Therapeutic Considerations for Older Adults with Head and Neck Cancer. Volume 18, 409-422 ○
- 1 Chemoradiation for Locoregionally Advanced Laryngeal Cancer. **2023**, 56, 285-293 ○